easysite
You are here > Services > Research and Development > Our current areas of Research > Cardiology Studies
.

Cardiology Studies

The dal-GenE trial

Evaluating the effects of study drug Dalcetrapib on reducing repeat cardiovascular events in a genetically defined population whom have recently had a heart attack.

Study area: Cardiology

Background: Dalcetrapib is an investigational drug that has been tested in several large clinical trials for its effect on reducing cardiovascular risk in those who have had a heart attack. Results to date have demonstrated that treatment with Dalcetrapib may significantly benefit people who have a particular gene (AA) variant.

Aim: To test the effect of Dalcetrapib only in patients with the AA variant to confirm these findings of cardiovascular benefit.

Who can participate:Anyone aged 45 years and over who has had a heart attack within the last 12 weeks. Exclusions apply; please contact us for more information.



If you would like any further information on the following studies, and to find out if you are eligible please contact:

 

Address: R&D office, C254, West Wing, Broomfield Hospital, Court Road, Chelmsford, Essex, CM1 7ET 

Telephone01245 515136
Email: Research@meht.nhs.uk